• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Decreased Fetal Movement: Quantifying Risk for Stillbirth and Other Adverse Outcomes

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Turner et al. (JAMA Network Open, 2021) examined the association of decreased fetal movement (DFM) and pregnancy outcomes in a setting where a management algorithm was in use

METHODS:

  • Cohort study (2009 to 2019)
    • Australia’s largest maternity hospital
  • Population
    • All singleton births
    • >28 weeks
    • No known congenital anomalies
  • Exposure
    • Presentation to hospital with DFM >28 weeks  
  • Study design
    • Multivariate analysis was used to account for covariates
  • Primary outcome
    • The incidence of stillbirth
  • Secondary outcomes
    • Obstetric intervention
    • Small for gestational age (SGA)
    • Composite adverse perinatal outcome ≥1 of the following: NICU admission | Severe acidosis (UA pH <7.0 or base excess ≤−12.0 mmol/L) | 5-minute Apgar score <4 | Stillbirth or neonatal death

RESULTS:

  • 101,597 pregnancies
    • Presented ≥1 episode of DFM: 8821 (8.7%)
    • No DFM (controls): 92 776 women (91.3%)
  • Women who presented with DFM were
    • Younger (P < 0.001)
      • DFM: mean age 30.4 years
      • Control mean age: 31.5 years
    • More likely to be nulliparous (P < 0.001)
      • DFM: 54.9%
      • Control: 45.5%
    • More likely to have had a previous stillbirth (P < 0.001)
      • DFM: 2.1%
      • Control: 1.2%
    • Less likely to have a previous cesarean delivery (P < 0.001)
      • DFM: 13.6%
      • Control: 18.8%

Risk for Stillbirth

  • Stillbirth rate during the study period (>28 weeks)
    • 2.0 per 1000 births
  • Overall, presenting with DFM was not associated with higher odds of stillbirth
    • DFM: 0.1% (9 women)
    • Control: 0.2% (185 women)
    • Adjusted odds ratio (aOR) 0.54 (95% CI, 0.23 to 1.26; P=0.16)
  • Odds of stillbirth were significantly higher in women with ≥2 presentations vs 1
    • aOR 4.96 (95% CI, 0.98 to 24.98; P=.05)
  • Presenting with DFM was associated with higher odds of
    • SGA: aOR 1.14 (95% CI, 1.03 to 1.27; P=0.01)
    • The composite adverse perinatal outcome: aOR 1.14 (95% CI, 1.02 to 1.27; P=0.02)
    • Planned early term birth: aOR 1.26 (95% CI, 1.15 to 1.38; P<0.001)
    • Induction of labor: aOR 1.63 (95% CI, 1.53 to 1.74; P<0.001)
    • Emergency cesarean delivery: aOR 1.18 (95% CI, 1.09 to 1.28; P<0.001)

CONCLUSION:

  • Overall, there was no significant difference in incidence of stillbirth between women with decreased fetal movement and the control population
  • Authors suggest that the lack of difference in stillbirth between groups, despite increased risk for adverse perinatal outcomes, may be due to enhanced awareness that leads to quickly seeking care if movements are perceived to be reduced

Learn More – Primary Sources:

Evaluation of Pregnancy Outcomes Among Women With Decreased Fetal Movements

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

How Well Can Perceived Changes in Fetal Movements Predict Stillbirth?
RCT Results: Can the Use of “Mindfetalness” to Assess Fetal Movements Decrease Adverse Pregnancy Outcomes?
The AFFIRM Trial: Does Maternal Awareness of Fetal Movement Counts Reduce Stillbirth Risk

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site